PubMed Health⌕ Search

Biomedical subjects

E Drapier-Faure

Publications and source records attributed to E Drapier-Faure.

29 records · Page 2Linked to original sources
PubMed1988

[Thermography of the breast. Sensitivity, specificity and reproducibility].

Thermography is a questionable method of diagnosis of breast diseases. In our study, we demonstrate that the low sensitivity and specificity is not related to the experience of the reader. One hundred thermograms were given to five different readers: three of them were thermographists, one was a gynecologist and the last one radiotherapist. Sixteen patients had a breast carcinoma, 18 had benign lesions. Seventy-two patients had no lesion at the time of diagnosis and 4 years after. The false negative and the false positive rates were not different according to the readers. The reproducibility, judged with the Kappa test, was poor. This study, in agreement with most of the previous studies, demonstrates that thermography must not be recommended neither for diagnosis nor for screening of breast diseases.

Breast Neoplasms↗
PubMed1987

[Observations on the new progestational agents].

The purpose of this article will be to present informations regarding two new progestational++ medications: nomegestrol acetate (Lutenyl), and promegestone (Surgestone) in order to make use of them in our prescription habits. We will situate them in relation to various groups of progestative medications and present their specific properties and their tolerance. Finally, we will demonstrate their role in contraception and their effectiveness in the main indications of progestative medications.

Contraceptive Agents, Female↗
PubMed1986

[A new therapeutic approach to infertility in polycystic ovaries: pure FSH].

Current, improved understanding of the physiopathology of polycystic ovary syndrome offers the possibility of more suitable treatment. Formerly, objectives differed for a given patient: re-establish regular cycles using progestogens or estroprogestogens, reduce hirsutism with antiandrogens, trigger ovulation. Clomid is the inducer of choice, but setbacks occur. Injectable gonadotropins were, in principle, a contraindication due to the high incidence of excess stimulation and multiple pregnancy. The introduction of purified FSH offers another method of stimulation. Severe excess stimulation is eliminated with a suitable protocol involving administration of small doses. This offers hope, but as yet no large-scale trial has been published.

Clomiphene↗
PubMed1985

[Functional hyperprolactinemia].

Treatment remains the same whether there is true idiopathic hyperprolactinemia or microadenomas too small to be detectable by methods of investigation. Bromocriptine has an antitumoral effect and treatment can often be stopped after the disappearance of a microadenoma or even of a larger adenoma. "Cure" of idiopathic hyperprolactinemia is rarer.

Adenoma↗
PubMedDate not supplied

[Acceptability of continuous combined versus cyclical HRT: a French multicentric randomized clinical study].

OBJECTIVES: To describe and compare acceptability of treatment and quality of life over 12 cycles in 2 groups of women randomised to continuous combined Climodiène (estradiol valerate 2 mg/dienogest 2 mg) or cyclic Climène (estradiol valerate 2 mg, from D1 to D21/cyproterone acetate 1 mg, from D12 to D21, followed by 7 days off), switching from previous sequential estroprogestative HRT because of side effects. PATIENTS AND METHODS: One hundred forty three postmenopausal women aged 54.39-years were recruited and randomised to Climène (N=68) or Climodiène (N=75). Acceptability was evaluated by the continuation rate in the 2 groups at the end of the 12 cycles study. Assessment of quality of life was obtained from the responses to the women's health questionnaire (WHQ) and to an ad hoc satisfaction questionnaire at baseline, and at the 12th cycle of treatment. RESULTS: No significant difference in baseline characteristics of volunteers were found in the 2 treatment groups except for the socioeconomic status (more town-dwellers in Climène group). Total WHQ score significantly improved after 12 months of treatment with Climène and Climodiène, respectively decreasing from 68.9 to 64.37 (-4.53) and from 69.95 to 62.06 (-7.89), with a trend towards higher improvement with Climodiène, particularly in the hot flushes subscale. In Climodiène group, a significant decrease in sleep problems and cognitive function subscales was found, which is consistent with previous polysomnography and psycho physiological measures data with Climodiène. The evolution of Satisfaction Index is positive and of the same magnitude in the 2 groups, showing an improvement at 12 months: respectively -2.79 (P=0.002) et -2.26 (P=0.02) for Climène and Climodiène. DISCUSSION AND CONCLUSIONS: Even though the benefit/risk ratio of the hormonal substitutive treatment is recognized effective against climateric symptoms which affect the quality of life, this work is the first randomised prospective study on the effects of Climodiène on quality of life in post-menopausal women assessed by the French validated version of the world-wide used WHQ. Decreases in "sleep problems" and "cognitive function" subscales scores in this study are of a magnitude clinically relevant and consistent with previous data on Climodiène impact on postmenopausal symptoms.

Cyproterone Acetate↗